A phase II trial demonstrated that the CD40 agonist sotigalimab combined with nivolumab induced durable responses in PD-1 inhibitor-resistant melanoma patients, achieving an ORR of 15.2% (5/33 partial responses) with a median duration of response ≥26 months. This evidence concerns the gene PDCD1 and melanoma.